1Niccolai E,Taddei A,Prisco D,et al.Gastric cancer and the epoch of immunotherapy approaches[J].World J Gastroenterol,2015,21(19):5.
2Kim JY,Ryoo HM,Bae SH,et al.Multi-center randomized phaseⅡstudy of weekly docetaxel versus weekly docetaxelplus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer[J].Anticancer Res,2015,35(6):3531-3536.
3Shi C,Chen Q,Shen S,et al.Paclitaxel combined with oxaliplatin as first-line chemotherapy for locally advanced or metastatic gastric cancer[J].Expert Rev Anticancer Ther,2015,15(5):595-601.
4Hacibekiroglu I,Kodaz H,Erdogan B,et al.Comparative analysis of the efficacy and safety of oxaliplatin plus 5-fluorouracil/leucovorin(modified FOLFOX6)with advanced gastric cancer patients having agood or poor performance status[J].Asian Pac J Cancer Prev,2015,16(6):2355-2259.
5Yamada Y,Higuchi K,Nishikawa K,et al.PhaseⅢstudy comparing oxaliplatin plus S-1 with cisplatin plus S-1in chemotherapy-naive patients with advanced gastric cancer[J].Ann Oncol,2015,26(1):141-148.
5Wilson WH, Gutierrez M,0' Connor P ,et al. The role of rituximab andchemotherapy in aggressive B-cell lymphoma : a preliminary report of dose-adjusted EPOCH-R[J). Semin Oncol,2002;29(t suppl2) :41-7.
6Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trialcomparing mitomycin,cisplatin,and protracted venous-infusion fluoroura-cil ( PVI 5-Fu) with epirubicin, cisplatin, and PIV 5-Fu in advancedesophagogastric cancer[J]. J Clin Oncol,2002;20(8) : 1996-2004.
7Neri B^Pantaleo P,Giommoni al. Oxaliplatin,5-fluorouracil/ leuco-vorin and epirubicin as first-line treatment in advanced gastric carcinoma :a phase II study[ J]. Br J Cancer,2007 ;96(7) : 1043-6.
8Takechi T,Okabe H,Ikeda K,et al. Correlations between antitumor activi-ties of fluoropyridines and DPD activity in lung tumor xenografts[ J]. On-col Rep,2005;14(l) :33-9.
9Sato A,Nakumachi M. Clinical development of chemotherapy for advancedgastric cancer[ J], Gan To Kaqaku Ryoho,2008 ;35 (9) : 1461-6.
10Koizumi W, Narahara H, Hara T ,et al. S-l plus cisplain versus S-l alonefor first-line treatment of advanced gastric cancer ( SPIRITS trial) : aphase IE trial[J]. Lancet Oncol,2008 ;9(3 ) :215-21.
